MAO-inhibitors were introduced as a remedy for depression in the 1950s and target the ability of a mitochondrial enzyme MAOA to contribute to the degradation of serotonin to its metabolic end-product 5-hydroxyindoleacetic acid (5-HIAA). The gene discussed is MAOA; the disease is depressive symptom measurement.